Valor Equity Partners
Valor Equity Partners, established in 1995 and headquartered in Chicago, Illinois, is a private equity firm specializing in operational growth investments. The firm partners with companies and entrepreneurs across various stages of development, focusing on those committed to excellence and industry transformation. Valor Equity typically invests $10-$30 million in companies generating $5-$15 million in EBITDA, targeting growth investments in sectors such as industrial products, manufacturing, infrastructure, and consumer goods. The firm's investment strategy includes both control and non-control positions, with initial investments ranging from $25 million to $75 million. Valor Equity Partners has a diverse investment portfolio, with a significant portion of its capital allocated to the technology sector.
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.
Loyal is a biotechnology company focused on developing veterinary pharmaceuticals aimed at extending the lifespan and improving the health span of dogs. By creating medications that target the aging process, Loyal seeks to delay or prevent the onset of age-related diseases, including cancer, heart disease, and metabolic disorders. The company's innovative approach involves quantifying and regulating the biological processes associated with aging, which helps to mitigate the severity of these ailments. Through its research and product development, Loyal strives to ensure that dogs can enjoy longer, healthier lives, ultimately benefiting both pets and their owners.
Spot & Tango
Series A in 2022
Spot & Tango is a human-grade dog food manufacturer based in New York City, focused on providing high-quality health and wellness products for pets. The company operates as a direct-to-consumer brand, offering fresh, nutritious, and sustainable dog food that is accessible to a wide range of customers. Their products are crafted by a team of experienced animal nutritionists, ensuring that the food meets specific dietary needs. Spot & Tango also provides personalized meal plans tailored to a dog's weight, activity level, and lifestyle. Additionally, the company emphasizes eco-friendly practices by delivering its products in sustainable packaging, reflecting a commitment to both pet health and environmental responsibility.
Spot & Tango
Series B in 2022
Spot & Tango is a human-grade dog food manufacturer based in New York City, focused on providing high-quality health and wellness products for pets. The company operates as a direct-to-consumer brand, offering fresh, nutritious, and sustainable dog food that is accessible to a wide range of customers. Their products are crafted by a team of experienced animal nutritionists, ensuring that the food meets specific dietary needs. Spot & Tango also provides personalized meal plans tailored to a dog's weight, activity level, and lifestyle. Additionally, the company emphasizes eco-friendly practices by delivering its products in sustainable packaging, reflecting a commitment to both pet health and environmental responsibility.
PetDx is a San Diego-based molecular diagnostics company focused on enhancing pet health through advanced genomic technologies. The company's primary offering, OncoK9, is a pioneering multi-cancer early detection test that allows veterinarians to identify cancer in dogs through a simple blood draw. This first-in-class liquid biopsy utilizes next-generation sequencing and proprietary bioinformatics to analyze genetic material, facilitating early detection, characterization, and management of cancer in pets. By providing a non-invasive testing option, PetDx supports veterinarians in delivering improved care and outcomes for canine patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.